Logo

AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma

Share this
AstraZeneca

AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma

Shots:

  • The approval was based on a P-III (MIRACLE) study that assessed the safety & efficacy of Fasenra (benralizumab) as maintenance therapy for severe eosinophilic asthma adults (n=695; age≥12). Currently approved in >80 countries globally (incl. US & EU)
  • Fasenra (30mg, SC, Q8W) achieved all 1EPs and key 2EPs vs PBO that shows reduced in AAER over 48 wks by 74% (0.49 vs 1.88) & 2EPs changed at 48wks in pre-bronchodilator FEV1 and TASS. Safety and tolerability were consistent with the known safety profile
  • Fasenra is being assessed in other indications such as COPD, CRSwNP, EGPA & hypereosinophilic syndrome. Fasenra is an in-license from BioWa (a subsidiary of Kyowa Kirin) and developed by AstraZeneca

Ref: AstraZeneca | Image: AstraZeneca

Related News: AstraZeneca Presents (XALOC) Programme Results of Fasenra (benralizumab) for the Treatment of Severe Eosinophilic Asthma at ERS 2022

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions